Premium Nahrungsergänzungsmittel | artgerecht

Hepatic Steatosis Index (HSI) – Fatty Liver Screening

The Hepatic Steatosis Index (HSI) is a scoring tool used to estimate the presence of a fatty liver using routine lab values and basic body measurements.

Regular tips about health Regular tips about health

Things worth knowing about "Hepatic Steatosis Index"

The Hepatic Steatosis Index (HSI) is a scoring tool used to estimate the presence of a fatty liver using routine lab values and basic body measurements.

What Is the Hepatic Steatosis Index?

The Hepatic Steatosis Index (HSI) is a clinically validated scoring tool designed to estimate the likelihood of hepatic steatosis – commonly known as fatty liver disease – using a small number of readily available parameters. Hepatic steatosis refers to the abnormal accumulation of fat within liver cells, affecting more than 5 % of hepatocytes. The HSI was developed as a cost-effective and non-invasive alternative to imaging procedures or liver biopsy for initial risk stratification.

How Is the Hepatic Steatosis Index Calculated?

The HSI is derived from the following parameters:

ALT (Alanine Aminotransferase) and AST (Aspartate Aminotransferase): liver enzymes measured in the blood
Body Mass Index (BMI): body weight relative to height
Biological sex (female/male)
Type 2 diabetes mellitus: present or absent

The formula is as follows:

HSI = 8 × (ALT / AST) + BMI (+ 2 if type 2 diabetes is present; + 2 if the patient is female)

An HSI score above 36 is considered indicative of fatty liver disease, while a score below 30 makes the diagnosis unlikely. Scores between 30 and 36 represent a grey zone in which further diagnostic workup is recommended.

Clinical Significance

Non-alcoholic fatty liver disease (NAFLD) is among the most prevalent liver conditions worldwide. Early detection is crucial, as untreated fatty liver can progress to serious complications such as liver fibrosis, liver cirrhosis, or even hepatocellular carcinoma. The HSI allows for rapid risk assessment in routine clinical practice without the immediate need for additional imaging or invasive procedures.

Indications for Use

The Hepatic Steatosis Index is applied in the following clinical contexts:

Screening of at-risk populations (e.g., overweight patients, individuals with type 2 diabetes, or metabolic syndrome)
Monitoring of known fatty liver disease during treatment
Epidemiological studies assessing the prevalence of hepatic steatosis in populations
Decision support for further diagnostic steps such as ultrasound or liver biopsy

Advantages and Limitations of the HSI

Advantages

Simple calculation using routine laboratory values
No additional costs for imaging required
Rapid applicability in everyday clinical use
Well validated across diverse population groups

Limitations

Not a substitute for a definitive diagnosis by imaging or biopsy
Limited accuracy in alcohol-related liver disease or other conditions affecting liver enzyme levels
The grey zone (30–36) requires further diagnostic clarification
Does not assess the severity of steatosis or degree of inflammatory activity

Diagnosis and Further Evaluation

When the HSI is elevated, further diagnostic evaluation may be warranted, including:

Liver ultrasound: imaging to visualize fat deposits within the liver
Elastography (FibroScan): measures liver stiffness to assess the degree of fibrosis
Liver biopsy: the gold standard for histological assessment, though invasive
Extended laboratory workup: including GGT, ferritin, lipid panel, and fasting blood glucose

Treatment of Fatty Liver Disease

Management of a confirmed fatty liver depends on the underlying cause and severity. General treatment strategies include:

Weight reduction through a calorie-reduced diet and regular physical activity
Alcohol abstinence in cases of alcohol-related liver disease
Optimization of blood glucose control in patients with diabetes mellitus
Treatment of comorbidities such as hypertension or dyslipidemia
Pharmacological therapy: currently approved medications specifically targeting NAFLD/NASH remain limited; novel treatment approaches are under active clinical investigation

References

Lee J.H. et al. - Hepatic Steatosis Index: A simple screening tool reflecting nonalcoholic fatty liver disease. Digestive and Liver Disease, 2010.
European Association for the Study of the Liver (EASL) - Clinical Practice Guidelines on Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 2016.
Chalasani N. et al. - The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (AASLD). Hepatology, 2018.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.